You are here

Press Release Archive

 
- Pfizer Declares 26-Cent Third-Quarter 2014 Dividend

The board of directors of Pfizer Inc. today declared a 26-cent third-quarter 2014 dividend on the company’s common stock, payable September 3, 2014, to shareholders of record at the close of business on August 1, 2014.

 
- James C. Smith Elected to Pfizer’s Board of Directors

 

Pfizer Inc. today announced the election of James C. Smith to its Board of Directors, effective immediately. Mr. Smith also was appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.

 
- Pfizer Invites Public to View and Listen to Webcast of July 29 Conference Call with Analysts

 

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 29, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2014 Performance Report, to be issued that morning.

 
- Two-Year Results From Pfizer’s XELJANZ® (Tofacitinib Citrate) ORAL Start Study Published in The New England Journal of Medicine

Pfizer Inc. (NYSE:PFE) announced today the publication of two-year results from the ORAL Start study in the June 19 issue of The New England Journal of Medicine.

 
- Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration

Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis’ CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient’s own T-cells to target tumor cells).

 
- Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine

Pfizer Inc. (NYSE:PFE) announced today that it has submitted a Biologics License Application (BLA) to the U.S.

 
- Pfizer Opens New State-of-the-Art Research and Development Site in Cambridge, Massachusetts

Pfizer Inc. (NYSE:PFE) announced today the opening of a new 280,000 square-foot Research and Development (R&D) hub in Cambridge, Mass. The new Pfizer facilities in Kendall Square bring together 1,000 colleagues from three area locations and position Pfizer in closer proximity to leading academic institutions, hospitals and patient organizations.

 
- Pfizer Announces Over 10 Abstracts for XELJANZ® (Tofacitinib Citrate) in Rheumatoid Arthritis to be Presented at the European League Against Rheumatism (EULAR) 2014 Annual Meeting

Pfizer Inc. announced today that over 10 abstracts have been accepted for presentation at the European League Against Rheumatism (EULAR) 2014 Annual Meeting (June 11-14, Paris, France), seven of which are focused on further characterizing the safety profile of XELJANZ (tofacitinib citrate) in treating moderately to severely active rheumatoid arthritis.

 
- Dr. Morris J. Birnbaum Joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research

Pfizer Inc. announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research. He will report directly to Rod MacKenzie, Ph.D., Group Senior Vice President and Head of PharmaTherapeutics Research & Development, and will be based in a key Pfizer R&D hub in Cambridge, MA.

 
- Pfizer and the Avon Foundation for Women Announce $1 Million Grants Program to Address Gaps in Support for People Living with Metastatic Breast Cancer

Despite the high level of public attention devoted to breast cancer awareness, more than 60 percent of respondents in a new national survey commissioned by Pfizer Inc. say they know little to nothing about metastatic breast cancer.1

 
- Pfizer Brings Frequent Heartburn Relief Over-the-Counter with New Nexium® 24HR

Pfizer Inc. (NYSE: PFE) today announced the introduction in the U.S.

 
- ANNOUNCEMENT REGARDING ASTRAZENECA PLC

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 
- Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis

Pfizer Inc. (NYSE:PFE) announced today detailed results from the Oral treatment Psoriasis Trial (OPT) Retreatment study (A3921111), a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis.

 
- New Survey Highlights The Impact Of Menopausal Symptoms On Women In The Workplace

A new national survey released today by Working Mother Media and Pfizer (NYSE:PFE) on the impact of menopausal symptoms on women in the workplace finds that managing menopausal symptoms in their work life is extremely or somewhat difficult for nearly half (48 percent) of working women ages 45-65 who have experienced these symptoms in the past year.

 
- Statement from Pfizer Inc.

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

19 May 2014

 
- Pfizer To Submit Palbociclib New Drug Application With FDA Based On Final Results Of PALOMA-1

Pfizer Inc. today announced that it will submit a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.